Slingshot members are tracking this event:

Amgen (AMGN) files supplemental Biologics License Application (sBLA) for Prolia (denosumab) in treating glucocorticoid-induced osteoporosis.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AMGN Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 31, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Glucocorticoid-induced Osteoporosis., Prolia, Denosumab, Sbla